Glenmark Pharmaceuticals receives ANDA approval for Norgestimate and Ethinyl Estradiol Tablets USP

24 Feb 2016 Evaluate

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for Norgestimate and Ethinyl Estradiol Tablets USP, 0.18 mg/0.025 mg, 0.215 mg/0.025 mg and 0.25 mg/0.025 mg, the generic version of Ortho Tri-Cyclen Lo Tablets of Janssen Pharmaceuticals, Inc.

According to IMS Health sales data for the 12 month period ending December 2015, the Ortho Tri-Cyclen Lo Tablets market achieved annual sales of approximately $503.9 million.

The company’s current portfolio consists of 107 products authorized for distribution in the U.S. marketplace and 62 ANDA’s pending approval with the USFDA. In addition to these internal filings, the company continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Glenmark Pharma Share Price

1972.40 -12.95 (-0.65%)
16-Dec-2025 10:26 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1781.70
Dr. Reddys Lab 1273.25
Cipla 1502.20
Zydus Lifesciences 922.30
Lupin 2089.70
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×